drugset / Trial / NCT00546676

Ketek in CAP / AECB in Ambulatory Adult Patients

NCT00546676

Phase 4 Completed 174 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the clinical effectiveness of telithromycin in the treatment of either CAP or AECB in a large population of ambulatory adult patients in a community-based setting.

Timeline

Start
2004-05
Primary completion
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Telithromycin Small molecule 800 mg Oral